AlphaMark Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.16M | Buy |
1,622
+9
| +0.6% | +$7.55K | 0.5% | 43 |
|
|
2024
Q3 | $1.7M | Sell |
1,613
-72
| -4% | -$80.1K | 0.59% | 34 |
|
|
2024
Q2 | $1.77M | Sell |
1,685
-56
| -3% | -$54.3K | 0.62% | 30 |
|
|
2024
Q1 | $1.68M | Sell |
1,741
-84
| -5% | -$79.9K | 0.59% | 31 |
|
|
2023
Q4 | $1.6M | Sell |
1,825
-3
| -0.2% | -$2.47K | 0.61% | 31 |
|
|
2023
Q3 | $1.5M | Sell |
1,828
-63
| -3% | -$49.5K | 0.64% | 30 |
|
|
2023
Q2 | $1.36M | Sell |
1,891
-424
| -18% | -$327K | 0.63% | 38 |
|
|
2023
Q1 | $1.9M | Buy |
2,315
+25
| +1% | +$18.9K | 0.85% | 31 |
|
|
2022
Q4 | $1.65M | Sell |
2,290
-10
| -0.4% | -$7.38K | 0.83% | 31 |
|
|
2022
Q3 | $1.58M | Buy |
2,300
+75
| +3% | +$47.2K | 0.78% | 31 |
|
|
2022
Q2 | $1.31M | Buy |
2,225
+9
| +0.4% | +$5.85K | 0.61% | 40 |
|
|
2022
Q1 | $1.55M | Sell |
2,216
-101
| -4% | -$63.9K | 0.57% | 44 |
|
|
2021
Q4 | $1.46M | Buy |
2,317
+48
| +2% | +$29.5K | 0.51% | 47 |
|
|
2021
Q3 | $1.37M | Sell |
2,269
-6
| -0.3% | -$3.73K | 0.5% | 47 |
|
|
2021
Q2 | $1.27M | Sell |
2,275
-17
| -0.7% | -$8.61K | 0.46% | 50 |
|
|
2021
Q1 | $1.08M | Sell |
2,292
-118
| -5% | -$57.5K | 0.41% | 51 |
|
|
2020
Q4 | $1.16M | Sell |
2,410
-1,875
| -44% | -$1.01M | 0.45% | 50 |
|
|
2020
Q3 | $2.4M | Sell |
4,285
-1,103
| -20% | -$669K | 0.99% | 35 |
|
|
2020
Q2 | $3.36M | Buy |
5,388
+29
| +0.5% | +$16.5K | 1.45% | 20 |
|
|
2020
Q1 | $2.62M | Sell |
5,359
-2,722
| -34% | -$1.12M | 1.45% | 23 |
|
|
2019
Q4 | $3.03M | Sell |
8,081
-929
| -10% | -$313K | 1.27% | 27 |
|
|
2019
Q3 | $2.5M | Buy |
9,010
+240
| +3% | +$71K | 1.08% | 40 |
|
|
2019
Q2 | $2.75M | Buy |
8,770
+1,225
| +16% | +$408K | 1.2% | 33 |
|
|
2019
Q1 | $3.1M | Buy |
7,545
+7,502
| +17,447% | +$3.09M | 1.31% | 32 |
|
|
2018
Q4 | $16K | Hold |
43
| – | – | 0.01% | 269 |
|
|
2018
Q3 | $17K | Hold |
43
| – | – | 0.01% | 303 |
|
|
2018
Q2 | $15K | Hold |
43
| – | – | 0.01% | 325 |
|
|
2018
Q1 | $15K | Hold |
43
| – | – | 0.01% | 313 |
|
|
2017
Q4 | $16K | Hold |
43
| – | – | 0.01% | 307 |
|
|
2017
Q3 | $19K | Buy |
43
+10
| +30% | +$4.76K | 0.01% | 284 |
|
|
2017
Q2 | $16K | Hold |
33
| – | – | 0.01% | 296 |
|
|
2017
Q1 | $13K | Hold |
33
| – | – | 0.01% | 308 |
|
|
2016
Q4 | $12K | Hold |
33
| – | – | 0.01% | 297 |
|
|
2016
Q3 | $13K | Hold |
33
| – | – | 0.01% | 229 |
|
|
2016
Q2 | $12K | Hold |
33
| – | – | 0.01% | 228 |
|
|
2016
Q1 | $12K | Hold |
33
| – | – | 0.01% | 220 |
|
|
2015
Q4 | $18K | Hold |
33
| – | – | 0.01% | 194 |
|
|
2015
Q3 | $15K | Hold |
33
| – | – | 0.01% | 197 |
|
|
2015
Q2 | $17K | Hold |
33
| – | – | 0.01% | 210 |
|
|
2015
Q1 | $15K | Sell |
33
-44
| -57% | -$18.6K | 0.01% | 215 |
|
|
2014
Q4 | $32K | Hold |
77
| – | – | 0.02% | 172 |
|
|
2014
Q3 | $28K | Hold |
77
| – | – | 0.02% | 175 |
|
|
2014
Q2 | $22K | Hold |
77
| – | – | 0.01% | 201 |
|
|
2014
Q1 | $23K | Hold |
77
| – | – | 0.01% | 185 |
|
|
2013
Q4 | $21K | Hold |
77
| – | – | 0.01% | 188 |
|
|
2013
Q3 | $24K | Sell |
77
-249
| -76% | -$65.5K | 0.02% | 189 |
|
|
2013
Q2 | $73K | Buy |
+326
| New | +$75.9K | 0.04% | 146 |
|
Other funds holding REGN
AlphaMark Advisors's REGN Position: Q4 2024 in Review
AlphaMark Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.56% in Q4 2024, buying an estimated $7.55K and bringing the position to 1,622 shares worth $1.16M. The position accounts for 0.5% of the portfolio, ranked #43.
AlphaMark Advisors first reported a position in REGN in Q2 2013 and has held it in 47 quarters since. The position peaked at $3.36M in Q2 2020. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.
- AlphaMark Advisors held 1,622 shares of Regeneron Pharmaceuticals worth $1.16M as of Q4 2024.
- AlphaMark Advisors bought 9 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $7.55K.
- Regeneron Pharmaceuticals made up 0.5% of AlphaMark Advisors's portfolio in Q4 2024, its #43 holding.
- AlphaMark Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- AlphaMark Advisors's Regeneron Pharmaceuticals position peaked at $3.36M in Q2 2020.
- 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.